by The next generation cancer diagnostics market size is poised to grow by USD 32.9 billion by 2032 from USD 15.2 billion in 2022, exhibiting a CAGR of 8.02% during the forecast period 2023-2032.
Key Takeaways
- By technology, next-generation sequencing accounted highest revenue share of around 37.1% in 2022.
- By application, the biomarker development segment has held the largest revenue share of around 40.8% in 2022.
- By application, the genetic analysis segment is expanding at a CAGR of 11.2% over the forecast period 2023 to 2032.
- By cancer type, breast cancer is expected to grow at a CAGR of 10.1% over the forecast period.
- By function, the therapeutic monitoring segment has dominated the market with a revenue share of 26% in 2022 whereas the prognostic diagnostics segment is expected to reach a CAGR of 10.2% during the forecast period.
- By region, North America accounted largest revenue share of 40.7% in 2022.
- The Asia Pacific region is poised to grow at a CAGR of 12.1% over the forecast period.
Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Next generation cancer diagnostics market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.
To begin with, the Next generation cancer diagnostics Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.
Get a Sample Report: https://www.precedenceresearch.com/sample/3246
Report Scope of the Next Generation Cancer Diagnostics Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 16.42 Billion |
| Market Size by 2032 | USD 32.9 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 8.02% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Technology, By Application, By Cancer Type, and By Function |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Hydraulic Tools and Equipment Market Size To Rake USD 71.33 Bn By 2032
The empirical study on the global Next generation cancer diagnostics market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Next generation cancer diagnostics Market. Our market report for the Next generation cancer diagnostics market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
Top Key Players:
- GE HealthCare
- Koninklijke Philips N.V.
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- QIAGEN
- Agilent Technologies, Inc. (Dako)
- Abbott
- Thermo Fisher Scientific Inc.
- Janssen Pharmaceuticals, Inc.
Data Sources and Methodology
To gather comprehensive insights on the Global Next generation cancer diagnostics Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Next generation cancer diagnostics Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Next generation cancer diagnostics market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Market Segmentation:
By Technology
- Next-generation Sequencing
- Lab-on-a-chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
- qPCR & Multiplexing
- Protein Microarrays
- DNA Microarrays
By Application
- Biomarker Development
- Proteomic Analysis
- CTC Analysis
- Epigenetic Analysis
- Genetic Analysis
By Cancer Type
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Cervical Cancer
- Others
By Function
- Therapeutic Monitoring
- Prognostics
- Companion Diagnostics
- Cancer Screening
- Risk Analysis
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Next generation cancer diagnostics market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Next generation cancer diagnostics market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Next generation cancer diagnostics market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Next generation cancer diagnostics market but also the strategic plans of industry leaders.
Table of Content
By Technology
- Next-generation Sequencing
- Lab-on-a-chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
- qPCR & Multiplexing
- Protein Microarrays
- DNA Microarrays
By Application
- Biomarker Development
- Proteomic Analysis
- CTC Analysis
- Epigenetic Analysis
- Genetic Analysis
By Cancer Type
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Cervical Cancer
- Others
By Function
- Therapeutic Monitoring
- Prognostics
- Companion Diagnostics
- Cancer Screening
- Risk Analysis
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Unlocking Market Insights through Data Excellence
The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
Precedence Statistics – Empowering Your Data Insights
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
